Literature DB >> 16257373

Keynote review: phosphodiesterase-4 as a therapeutic target.

Miles D Houslay1, Peter Schafer, Kam Y J Zhang.   

Abstract

Cyclic AMP (cAMP) is a key second messenger in all cells. It is compartmentalized within cells and its levels are controlled, as a result of spatially discrete signaling cassettes controlling its generation, detection and degradation. Underpinning compartmentalized cAMP signaling are approximately 20 members of the phosphodiesterase-4 (PDE4) family. The selective inhibition of this family generates profound, functional effects and PDE4 inhibitors are currently under development to provide potential, novel therapeutics for the treatment of inflammatory diseases, such as asthma, chronic obstructive pulmonary disease and psoriasis, as well as treating depression and serving as cognitive enhancers. Here, we delineate the range of PDE4 isoforms, their role in signaling, their structural biology and related preclinical and clinical pharmacology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257373     DOI: 10.1016/S1359-6446(05)03622-6

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  196 in total

1.  A novel phenylpyridazinone, T-3999, reduces the progression of autoimmune myocarditis to dilated cardiomyopathy.

Authors:  Fadia Ali Kamal; Kenichi Watanabe; Meilei Ma; Yuichi Abe; Reyad Elbarbary; Makoto Kodama; Yoshifusa Aizawa
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

2.  Association of PDE4B polymorphisms and schizophrenia in Northwestern Han Chinese.

Authors:  Fanglin Guan; Chen Zhang; Shuguang Wei; Hongbo Zhang; Xiaomin Gong; Jiali Feng; Chengge Gao; Rong Su; Huanming Yang; Shengbin Li
Journal:  Hum Genet       Date:  2011-12-11       Impact factor: 4.132

Review 3.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  CFTR regulation in human airway epithelial cells requires integrity of the actin cytoskeleton and compartmentalized cAMP and PKA activity.

Authors:  Stefania Monterisi; Maria Favia; Lorenzo Guerra; Rosa A Cardone; Domenico Marzulli; Stephan J Reshkin; Valeria Casavola; Manuela Zaccolo
Journal:  J Cell Sci       Date:  2012-02-02       Impact factor: 5.285

5.  Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.

Authors:  Mahomi Kuroiwa; Gretchen L Snyder; Takahide Shuto; Atsuo Fukuda; Yuchio Yanagawa; David R Benavides; Angus C Nairn; James A Bibb; Paul Greengard; Akinori Nishi
Journal:  Psychopharmacology (Berl)       Date:  2011-08-11       Impact factor: 4.530

6.  Distinct roles of adenylyl cyclase VII in regulating the immune responses in mice.

Authors:  Biyan Duan; Richard Davis; Eva L Sadat; Julie Collins; Paul C Sternweis; Dorothy Yuan; Lily I Jiang
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

7.  New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies.

Authors:  Sara Guariento; Olga Bruno; Paola Fossa; Elena Cichero
Journal:  Mol Divers       Date:  2015-08-20       Impact factor: 2.943

Review 8.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

9.  Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2015-09-23       Impact factor: 5.000

10.  Ferulic acid prevents LPS-induced up-regulation of PDE4B and stimulates the cAMP/CREB signaling pathway in PC12 cells.

Authors:  Hao Huang; Qian Hong; Hong-Ling Tan; Cheng-Rong Xiao; Yue Gao
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.